Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 12Peripheral Blood Stem Cell Transplantation 10fludarabine phosphate 7Cyclosporine 7Mycophenolic Acid 6Busulfan 6Methotrexate 5Melphalan 4Idarubicin 4Filgrastim 4Etoposide 4Clofarabine 4aldesleukin 3Whole-Body Irradiation 3Tacrolimus 3Radiotherapy 3Mitoxantrone 3Flow Cytometry 3Daunorubicin 3Cyclophosphamide 3Antilymphocyte Serum 3Transplantation 2Radiotherapy, Intensity-Modulated 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Cytogenetic Analysis 2Bortezomib 2Alemtuzumab 2tipifarnib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Congenital Abnormalities × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡